Repurposing of Secukinumab as Neuroprotective in Cuprizone-Induced Multiple Sclerosis Experimental Model via Inhibition of Oxidative, Inflammatory, and Neurodegenerative Signaling
Authors:
- 8 June 2020
- journal article
- research article
- Published by Springer Nature in Molecular Neurobiology
- Vol. 57 (8) , 3291-3306
Abstract
Multiple sclerosis (MS) is a chronic, inflammatory, and neurodegenerative autoimmune disease. MS is a devastating disorder that is characterized by cognitive and motor deficits. Cuprizone-induced demyelination is the most widely experimental model used for MS. Cuprizone is a copper chelator that is well characterized by microgliosis and astrogliosis and is reproducible for demyelination and remyelination. Secukinumab (SEC) is a fully human monoclonal anti-human antibody of the IgG1/kappa isotype that selectively targets IL-17A. Expression of IL-17 is associated with MS. Also, IL-17 stimulates microglia and astrocytes resulting in progression of MS through chemokine production and neutrophil recruitment. This study aimed to investigate the neuroprotective effects of SEC on cuprizone-induced demyelination with examining the underlying mechanisms. Locomotor activity, short-term spatial memory function, staining by Luxol Fast Blue, myelin basic protein, gliasosis, inflammatory, and oxidative-stress markers were assessed to evaluate neuroprotective, anti-inflammatory and antioxidant effects. Moreover, the safety profile of SEC was evaluated. The present study concludes the efficacy of SEC in Cup-induced demyelination experimental model. Interestingly, SEC had neuroprotective and antioxidant effects besides its anti-inflammatory effect in the studied experimental model of MS. Graphical abstractKeywords
This publication has 80 references indexed in Scilit:
- The Cognitive Neuroscience of Human Memory Since H.M.Annual Review of Neuroscience, 2011
- Transgenic models for cytokine-induced neurological diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2010
- Astrocyte-Restricted Ablation of Interleukin-17-Induced Act1-Mediated Signaling Ameliorates Autoimmune EncephalomyelitisImmunity, 2010
- Inhibiting poly(ADP-ribose) polymerase: a potential therapy against oligodendrocyte deathBrain, 2010
- The Nuclear Factor NF- B Pathway in InflammationCold Spring Harbor Perspectives in Biology, 2009
- Functional interleukin-17 receptor A is expressed in central nervous system glia and upregulated in experimental autoimmune encephalomyelitisJournal of Neuroinflammation, 2009
- The Nrf2–ARE PathwayAnnals of the New York Academy of Sciences, 2008
- Astrocytes in multiple sclerosis: A product of their environmentCellular and Molecular Life Sciences, 2008
- Heme oxygenase–1 and carbon monoxide suppress autoimmune neuroinflammationJournal of Clinical Investigation, 2007
- Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitisJournal of Experimental Medicine, 2006